Global Research Report explore the Status Epilepticus Clinical Trials Review, H2, 2016


“The Report Status Epilepticus Global Clinical Trials Review, H2, 2016 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. –”

GlobalData’s clinical trial report, Status Epilepticus Global Clinical Trials Review, H2, 2016″ provides an overview of Status Epilepticus clinical trials scenario. This report provides top line data relating to the clinical trials on Status Epilepticus. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

View Report At :


– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Reasons to buy

– Assists in formulating key business strategies with regards to investment

– Helps in identifying prominent locations for conducting clinical trials which saves time and cost

– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

– Supports understanding of trials count and enrollment trends by country in global therapeutics market

– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

– Facilitates clinical trial assessment of the indication on a global, regional and country level

Download Sample copy of this Report at :

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

Clinical Trials by Region 6

Clinical Trials and Average Enrollment by Country 7

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9

Top Five Countries Contributing to Clinical Trials in Europe 10

Top Countries Contributing to Clinical Trials in North America 11

Top Countries Contributing to Clinical Trials in Middle East and Africa 12

Clinical Trials by G7 Countries: Proportion of Status Epilepticus to Central Nervous System Clinical Trials 13

Clinical Trials by Phase in G7 Countries 14

Clinical Trials in G7 Countries by Trial Status 15

Clinical Trials by E7 Countries: Proportion of Status Epilepticus to Central Nervous System Clinical Trials 16

Clinical Trials by Phase in E7 Countries 17

Clinical Trials in E7 Countries by Trial Status 18

Clinical Trials by Phase 19

In Progress Trials by Phase 20

Clinical Trials by Trial Status 21

Clinical Trials by End Point Status 22

Subjects Recruited Over a Period of Time 23

Clinical Trials by Sponsor Type 24

Prominent Sponsors 25

Top Companies Participating in Status Epilepticus Therapeutics Clinical Trials 26

Prominent Drugs 28

Latest Clinical Trials News on Status Epilepticus 29

Jun 22, 2016: Marinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV 29

Jun 13, 2016: Marinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures 29

Apr 19, 2016: Marinus Pharmaceuticals Ganaxolone IV Demonstrates Robust Efficacy in Benzodiazepine-Resistant Model of Status Epilepticus 30

Clinical Trial Profile Snapshots 31

Appendix 59

Abbreviations 59

Definitions 59

Research Methodology 60

Secondary Research 60

About GlobalData 61

Contact Us 61

Disclaimer 61

Source 62

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074